ReviewFrontiers in pharmacology2025
Nephroprotective effects of substances of medicine food homology and traditional Chinese medicine phytochemicals against acute kidney injury.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Development and Preclinical Safety Evaluation of an Injectable β-Caryophyllene Nanoemulsion.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Natural compounds targeting inflammatory signaling and cell adhesion molecules in ischemic acute kidney injury.Archives of pharmacal research · 2026Review
- Identification of Key Bioactive Compounds of Medicine-Food Homologous Substances and Their Multi-Target Intervention Effects in Osteosarcoma Treatment.International journal of molecular sciences · 2026Article
- Moroccan Pinus pinaster bark as a dual in vivo and in silico nephroprotective agent against nephrocalcinosis: toxicity and ADMET insights.Urolithiasis · 2026Article
- Modulating regulated cell death: mechanistic insights into traditional Chinese medicine metabolites for ischemia/reperfusion-induced acute kidney injury.Frontiers in pharmacology · 2026Review
- Protection against cisplatin-induced acute kidney injury by hellgrammite extract: insights from comprehensive metabolomics.Frontiers in pharmacology · 2026Article
- Pharmacological potential of Chinese botanical drugs in managing chronic kidney disease by targeting mitochondrial quality control.Frontiers in pharmacology · 2025Review
- Molecular mechanisms and therapeutic advances of peritubular capillary neogenesis in acute kidney injury.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) represents significant medical challenges due to its elevated rates of morbidity and mortality, with limited therapeutic options currently available. Hence, the exploration of novel medicinal treatments for AKI management remains vital. Substances of medicine food homology (SMFH), referring to substances having characteristics of both food and medicine, have been applied in China for thousands years.They could be used for daily diets and body conditioning. Traditional Chinese medicine (TCM), with its naturally derived components and demonstrated effectiveness, presents distinctive benefits in AKI treatment. Numerous studies have shown that SMFH and TCM phytochemicals could function satisfactorily with nephroprotective effects and have a significant effect on alleviating AKI as well as its complications. In this review, the pathogenesis of AKI was illustrated. We concentrated on SMFH and TCM phytochemicals against AKI and tried to summarize the underlying mechanisms in various kinds of AKI, highlighting the crucial phytochemical components in AKI prevention and therapy. Besides, strategies for SMFH and TCM phytochemicals globalization are analysed. This review comprehensively reveals that SMFH and TCM phytochemicals exhibit promising potential for AKI intervention by targeting various signal pathways and targets, which would contribute to AKI's cognition, preventive treatments, as well as global promotion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.